NOW RECRUITING: Patients with Pulmonary Arterial Hypertension (PAH) for IMPAHCT,
a Phase 2b/3 study evaluating AV-101. Learn more about the study.

Marco Verwijs

Marco has over 15 years of product development and manufacturing experience. He has worked on multiple commercial products, leading them from clinical product development through NDA filing and commercial launch. He joins Aerovate from Vertex, where he helped develop Kalydeco and Orkambi, Flexion Therapeutics, where he helped develop and launch Zilretta, and most recently Epizyme, where he helped develop and launch Tazverik.